IP Library › Granted Patent US 12,376,573
Granted Patent B2
US 12,376,573 · App. 17/709,150 · Granted Aug 5, 2025

Genetically modified mice comprising humanized cellular immune system components with improved diversity of TCRB repertoire

Inventors: Chunguang Guo (Briarcliff Manor, NY); Naxin Tu (Pleasantville, NY); Andrew J. Murphy (Croton-on-Hudson, NY)
Assignee: Regeneron Pharmaceuticals, Inc.
A01K67/0278C07K14/7051C07K14/70514C07K14/70517C07K14/70539C12N5/0606A01K2217/072A01K2227/105A01K2267/0387
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,376,573
App. No.
17/709,150
Granted
Aug 5, 2025
Kind
B2
Abstract

Disclosed herein are non-human animals (e.g., rodents, e.g., mice or rats) genetically engineered to express a human or humanized T cell receptor (TCR) from a human or humanized TCR locus comprising a non-human TCR non-coding sequence, and optionally a humanized T cell co-receptor (e.g., humanized CD4 and/or CD8 (e.g., CD8α and/or CD8β)), and/or a human or humanized major histocompatibility complex that binds the humanized T cell co-receptor (e.g., human or humanized MHC II (e.g., MHC II α and/or MHC II β chains) and/or MHC I (e.g., MHC Iα) respectively, and optionally human or humanized β2 microglobulin). Also provided are embryos, tissues, and cells expressing the same. Methods for making the genetically engineered animals are also provided. Methods for using the genetically engineered animals for developing human therapeutics are also provided.

Claims (144)

1. A mouse cell comprising:

(A) an unrearranged T cell receptor (TCR) α variable region sequence that:

(i) comprises unrearranged human TCR α (TCRA) gene segments that comprise at least one functional unrearranged human T cell variable region Vα gene segment and at least one functional unrearranged human T cell variable region Jα gene segment, and

(ii) is operably linked to a mouse TCR α constant gene sequence, which is optionally at an endogenous mouse TCR α variable gene locus, and

(B) an unrearranged TCR β variable region sequence that:

(i) comprises unrearranged human TCR β (TCRB) gene segments that comprise at least one functional unrearranged human T cell variable region Vβ gene segment, a functional unrearranged human T cell variable region Dβ gene segment and a functional unrearranged human T cell variable region Jβ gene segment from each of a TCRBDJ1 cluster and a TCRBDJ2 cluster, and

(ii) is operably linked to a mouse TCR β constant gene sequence, which is optionally at an endogenous mouse TCR β variable gene locus,

wherein the unrearranged TCR β variable region sequence further comprises: (i) a mouse TCRBDJ1 non-coding sequence between the functional unrearranged human T cell variable region Dβ gene segment and the functional unrearranged human T cell variable region Jβ gene segment from the TCRBDJ1 cluster and (ii) a mouse TCRBDJ2 non-coding sequence between the functional unrearranged human T cell variable region Dβ gene segment and the functional unrearranged human T cell variable region Jβ gene segment from the TCRBDJ2 cluster,

wherein each of the unrearranged TCR α variable region sequence and the unrearranged TCR β variable region sequence is capable of rearranging in a T cell to encode a human or humanized T cell receptor variable α domain and a human or humanized T cell receptor variable β domain, respectively.

2. The mouse cell of claim 1 , wherein:

(A) the unrearranged TCR α variable region sequence comprises a full repertoire of functional unrearranged human T cell variable region Vα gene segments and a full repertoire of functional unrearranged human T cell variable region Jα gene segments, and

(B) the unrearranged TCR β variable region sequence comprises a full repertoire of functional unrearranged human Vβ gene segments and a full repertoire of functional unrearranged human Jβ gene segments.

3. The mouse cell of claim 1 , wherein:

(I) an endogenous mouse TCR α variable gene locus comprises a deletion selected from the group consisting of

(a) a deletion of all endogenous TCR Vα gene segments,

(b) a deletion of all endogenous TCR Jα gene segments, and

(c) a combination thereof, and/or

(II) an endogenous mouse TCR β variable gene locus comprises a deletion selected from the group consisting of

(a) a deletion of all endogenous TCR Vβ gene segments,

(b) a deletion of all endogenous TCR Dβ gene segments,

(c) a deletion of all endogenous TCR Jβ gene segments, and

(d) a combination thereof.

4. The mouse cell of claim 1 , wherein

(I) an endogenous mouse TCR α variable gene locus comprises a replacement selected from the group consisting of

(a) a replacement of at least one endogenous T cell variable region Vα gene segment with the at least one functional unrearranged human T cell variable region Vα gene segment,

(b) a replacement of at least one endogenous T cell variable region Jα gene segment with the at least one functional unrearranged human T cell variable region Jα gene segment, and

(c) a combination thereof, and/or

(II) an endogenous mouse TCR β variable gene locus comprises a replacement selected from the group consisting of

(a) a replacement of at least one endogenous T cell variable region Vβ gene segment with the at least one functional unrearranged human T cell variable region Vβ gene segment,

(b) a replacement of an endogenous T cell variable region Dβ1 gene segment with a functional unrearranged human T cell variable region Dβ1 gene segment, a replacement of an endogenous T cell variable region Dβ2 gene segment with a functional unrearranged human T cell variable region Dβ2 gene segment,

(c) a replacement of at least one endogenous T cell variable region Jβ1 gene segment with at least one functional unrearranged human T cell variable region Jβ1 gene segment and a replacement of at least one endogenous T cell variable region Jβ2 gene segment with at least one functional unrearranged human T cell variable region Jβ2 gene segment, and

(d) a combination thereof.

5. The mouse cell of claim 1 , wherein

(I) the unrearranged TCR α variable region sequence is positioned at an endogenous mouse TCR α variable gene locus such that the endogenous mouse TCR α variable gene locus comprises:

(a) a replacement of all endogenous T cell variable region Vα gene segments with all unrearranged human T cell variable region Vα gene segments from TRAV1-1 to TRAV41, and

(b) a replacement of all endogenous T cell variable region Jα gene segments with all unrearranged human T cell variable region Jα gene segments from TRAJ1 to TRAJ61; and

(II) the unrearranged TCR β variable region sequence is positioned at an endogenous mouse TCR β variable gene locus such that the endogenous mouse TCR β variable gene locus comprises:

(a) a replacement of all contiguous endogenous T cell variable region Vβ gene segments with all unrearranged human T cell variable region Vβ gene segments from TRBV1 to TRBV29-1,

(b)(i) a replacement of an endogenous tcrbdj1 cluster with a humanized TCRBDJ1 cluster comprising an unrearranged human TCRBD1 gene segment and (ii) each of an unrearranged human TCRBJ1-1 gene segment, an unrearranged human TCRBJ1-2 gene segment, an unrearranged human TCRBJ1-3 gene segment, an unrearranged human TCRBJ1-4 gene segment, an unrearranged human TCRBJ1-5 gene segment, and an unrearranged human TCRBJ1-6 gene segment,

wherein the humanized TCRBDJ1 cluster comprises a mouse TCRBDJ1 non-coding sequence between the unrearranged human TCRBD1 gene segment and the unrearranged human TCRBJ1-1 gene segment, and a mouse TCRBDJ1 non-coding sequence between any two consecutive unrearranged human TCRBJ1 gene segments, optionally wherein the unrearranged human TCRBD1 and TCRBJ1 gene segments flank the same mouse TCRBDJ1 non-coding sequences as are normally flanked by the corresponding mouse tcrbdj1 gene segments, and

(c)(i) a replacement of an endogenous tcrbdj2 cluster with a humanized TCRBDJ2 cluster comprising an unrearranged human TCRBD2 gene segment and (ii) each of an unrearranged human TCRBJ2-1 gene segment, an unrearranged human TCRBJ2-2 gene segment, an unrearranged human TCRBJ2-3 gene segment, an unrearranged human TCRBJ2-4 gene segment, an unrearranged human TCRBJ2-5 gene segment, an unrearranged human TCRBJ2-6 gene segment, and an unrearranged human TCRBJ2-7 gene segment,

wherein the humanized TCRBDJ2 cluster comprises a mouse TCRBDJ2 non-coding sequence between the unrearranged human TCRBD2 gene segment and any unrearranged human TCRBJ2 gene segment and a mouse TCRBDJ2 non-coding sequence between any two consecutive unrearranged human TCRBJ2 gene segments, optionally wherein the unrearranged human TCRBD2 and TCRBJ2 gene segments flank the same mouse TCRBDJ2 non-coding sequences as are normally flanked by the corresponding mouse tcrbdj2 gene segments.

6. The mouse cell of claim 5 , further comprising:

(a) a first nucleotide sequence encoding a chimeric human/mouse CD4 co-receptor that comprises D1, D2 and D3 domains of a human CD4 polypeptide operably linked to D4, transmembrane and cytoplasmic domains of a mouse CD4 polypeptide;

(b) a second nucleotide sequence encoding a chimeric human/mouse CD8α polypeptide and a third nucleotide sequence encoding a chimeric human/mouse CD8β polypeptide,

wherein the chimeric human/mouse CD8α polypeptide comprises an IgV-like domain of a human CD8α polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse CD8α polypeptide and wherein the chimeric human/mouse CD8β polypeptide comprises an IgV-like domain of a human CD8β polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse CD8β polypeptide;

(c) a fourth nucleotide sequence encoding a chimeric human/mouse MHC II a polypeptide and a fifth nucleotide sequence encoding a chimeric human/mouse MHC II B polypeptide,

wherein the chimeric human/mouse MHC II α polypeptide comprises α1 and α2 domains of a human HLA class II α polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse MHC II α polypeptide and wherein the chimeric human/mouse MHC II β polypeptide comprises β1 and β2 domains of a human HLA class II β polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse MHC II β polypeptide; and

(d) a sixth nucleotide sequence encoding a chimeric human/mouse MHC I polypeptide comprising α1, α2, and α3 domains of a human HLA class I polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse MHC class I polypeptide; and

(e) a β2 microglobulin locus encoding a human or humanized β2 microglobulin polypeptide.

7. A method of making a cell, comprising modifying a mouse cell to comprise in operable linkage with an endogenous TCR β constant gene sequence, an unrearranged TCR β variable region sequence, wherein the unrearranged TCR β variable region sequence comprises unrearranged human TCRB gene segments that comprise at least one functional unrearranged human T cell variable region Vβ gene segment, and a functional unrearranged human T cell variable region Dβ gene segment and a functional unrearranged human T cell variable region Jβ gene segment from each of a TCRBDJ1 cluster and a TCRBDJ2 cluster,

wherein the unrearranged TCR β variable region sequence further comprises (i) a mouse TCRBDJ1 non-coding sequence between the functional unrearranged human T cell variable region Dβ gene segment and the functional unrearranged human T cell variable region Jβ gene segment from the TCRBDJ1 cluster and (ii) a mouse TCRBDJ2 non-coding sequence between the functional unrearranged human T cell variable region Dβ gene segment and the functional unrearranged human T cell variable region Jβ gene segment from the TCRBDJ2 cluster, and

wherein the unrearranged TCR β variable region sequence is capable of rearranging in a T cell to encode a human or humanized T cell variable β domain.

8. The method of claim 7 , wherein the method comprises replacing a contiguous mouse TCRB sequence comprising a mouse TCRBD gene segment and a mouse TCRBJ gene segment with a nucleic acid sequence comprising at least one functional unrearranged human T cell variable region Dβ gene segment, a mouse TCRBD-TCRBJ non-coding sequence, and at least one functional unrearranged human T cell variable region Jβ gene segment, such that the at least one functional unrearranged human T cell variable region Dβ gene segment, the mouse TCRBD-TCRBJ non-coding sequence, and the at least one functional unrearranged human T cell variable region Jβ gene segment are contiguous and operably linked to the endogenous TCR β constant gene sequence.

9. The method of claim 8 , further comprising modifying the mouse cell to comprise:

(a) a first nucleotide sequence encoding a chimeric human/mouse CD4 co-receptor that comprises D1, D2 and D3 domains of a human CD4 polypeptide and transmembrane and cytoplasmic domains of a mouse CD4 polypeptide;

(b) a second nucleotide sequence encoding a chimeric human/mouse CD8α polypeptide and a third nucleotide sequence encoding a chimeric human/mouse CD8β polypeptide,

wherein the chimeric human/mouse CD8α polypeptide comprises an IgV-like domain of a human CD8α polypeptide and transmembrane and cytoplasmic domains of a mouse CD8α polypeptide,

wherein the chimeric human/mouse CD8β polypeptide comprises an IgV-like domain of a human CD8β polypeptide and transmembrane and cytoplasmic domains of a mouse CD8β polypeptide;

(c) a fourth nucleotide sequence encoding a chimeric human/mouse MHC II α polypeptide and a fifth nucleotide sequence encoding a chimeric human/mouse MHC II β polypeptide,

wherein the chimeric human/mouse MHC II α polypeptide comprises α1 and α2 domains of a human HLA class II α polypeptide and transmembrane and cytoplasmic domains of a mouse MHC II α polypeptide,

wherein the chimeric human/mouse MHC II β polypeptide comprises β1 and β2 domains of a human HLA class II β polypeptide and transmembrane and cytoplasmic domains of a mouse MHC II β polypeptide;

(d) a sixth nucleotide sequence encoding a chimeric human/mouse MHC I polypeptide,

wherein the chimeric human/mouse MHC I polypeptide comprises α1, α2, and α3 domains of a human HLA class I polypeptide and transmembrane and cytoplasmic domains of a mouse MHC I polypeptide;

(e) an unrearranged TCR α variable region sequence, wherein the unrearranged TCR α variable region sequence comprises at least one functional unrearranged human T cell variable region Vα gene segment and at least one functional unrearranged human T cell variable region Jα gene segment operably linked to a mouse TCRa constant gene sequence; and

(f) optionally, a β2 microglobulin locus encoding a human or humanized β2 microglobulin polypeptide.

10. The method of claim 9 , wherein modifying comprises homologous recombination in one or more mouse ES cell(s) such that the first, second, third, fourth, fifth, and sixth nucleotide sequences; the unrearranged TCR α variable region sequence and unrearranged TCR β variable region sequence; and optionally the β2 microglobulin locus; are added, in any order, into the genome of the one or more mouse ES cell(s).

11. A method of making a mouse, comprising generating a mouse from the one or more mouse ES cell(s) of claim 10 .

12. The mouse cell of claim 1 , wherein the mouse cell is an embryonic stem cell.

13. The mouse cell of claim 12 , further comprising:

(a) a first nucleotide sequence encoding a chimeric CD4 co-receptor that comprises D1, D2 and D3 domains of a human CD4 polypeptide and transmembrane and cytoplasmic domains of a mouse CD4 polypeptide,

(b) a second nucleotide sequence and a third nucleotide sequence respectively encoding a chimeric CD8α polypeptide and a chimeric CD8β polypeptide,

wherein the chimeric CD8α polypeptide comprises an IgV-like domain of a human CD8α polypeptide and transmembrane and cytoplasmic domains of a mouse CD8α polypeptide,

wherein the chimeric CD8β polypeptide comprises an IgV-like domain of a human CD8β polypeptide and transmembrane and cytoplasmic domains of a mouse CD8β polypeptide, and

(c) a fourth nucleotide sequence and a fifth nucleotide sequence respectively encoding a chimeric MHC II α polypeptide and a chimeric MHC II β polypeptide,

wherein the chimeric MHC II α polypeptide comprises α1 and α2 domains of a human HLA class II α polypeptide and transmembrane and cytoplasmic domains of a mouse MHC II a polypeptide,

wherein the chimeric MHC II β polypeptide comprises β1 and β2 domains of a human HLA class II β polypeptide and transmembrane and cytoplasmic domains of a mouse MHC II B polypeptide, and

(d) a sixth nucleotide sequence encoding a chimeric MHC I polypeptide,

wherein the chimeric MHC I polypeptide comprises α1, α2, and α3 domains of a human HLA class I polypeptide and transmembrane and cytoplasmic domains of a mouse MHC I polypeptide.

14. The mouse cell of claim 13 , wherein

(a) the first nucleotide sequence is present at an endogenous CD4 T cell co-receptor locus;

(b) the second nucleotide sequence is present at an endogenous CD8α T cell co-receptor locus, and the third nucleotide sequence is present at an endogenous CD8β T cell co-receptor locus;

(c) the fourth nucleotide sequence is present at an endogenous MHC II α locus and the fifth nucleotide sequence is present at an endogenous MHC II β locus;

(d) the sixth nucleotide sequence is present at an endogenous MHC I locus; and/or

(e) the unrearranged TCR α variable region sequence is present at an endogenous TCRα variable region locus and the unrearranged TCR β variable region sequence is present at an endogenous TCRβ variable region locus.

15. A mouse embryonic stem(ES) cell made by the method of claim 7 .

16. A mouse comprising:

(A) an unrearranged T cell receptor (TCR) α variable region sequence that:

(i) comprises unrearranged human TCR α (TCRA) gene segments that comprise at least one functional unrearranged human T cell variable region Vα gene segment and at least one functional unrearranged human T cell variable region Jα gene segment, and

(ii) is operably linked to a mouse TCR α constant gene sequence, which is optionally at an endogenous mouse TCR α variable gene locus, and

(B) an unrearranged TCR β variable region sequence that:

(i) comprises unrearranged human TCR β (TCRB) gene segments that comprise at least one functional unrearranged human T cell variable region Vβ gene segment, a functional unrearranged human T cell variable region Dβ gene segment and a functional unrearranged human T cell variable region Jβ gene segment from each of a TCRBDJ1 cluster and a TCRBDJ2 cluster, and

(ii) is operably linked to a mouse TCR β constant gene sequence, which is optionally at an endogenous mouse TCR β variable gene locus,

wherein the unrearranged TCR β variable region sequence further comprises: (i) a mouse TCRBDJ1 non-coding sequence between the functional unrearranged human T cell variable region Dβ gene segment and the functional unrearranged human T cell variable region Jβ gene segment from the TCRBDJ1 cluster and (ii) a mouse TCRBDJ2 non-coding sequence between the functional unrearranged human T cell variable region Dβ gene segment and the functional unrearranged human T cell variable region Jβ gene segment from the TCRBDJ2 cluster,

wherein each of the unrearranged TCR α variable region sequence and the unrearranged TCR β variable region sequence is capable of rearranging in a T cell to encode a human or humanized T cell receptor variable α domain and a human or humanized T cell receptor variable β domain, respectively,

and wherein the mouse expresses, on the T cell, the human or humanized T cell receptor variable α domain and the human or humanized T cell receptor variable β domain.

17. The mouse of claim 16 , wherein:

(A) the unrearranged TCR α variable region sequence comprises a full repertoire of functional unrearranged human T cell variable region Vα gene segments and a full repertoire of functional unrearranged human T cell variable region Jα gene segments, and

(B) the unrearranged TCR β variable region sequence comprises a full repertoire of functional unrearranged human Vβ gene segments and a full repertoire of functional unrearranged human Jβ gene segments.

18. The mouse of claim 16 , wherein:

(I) an endogenous mouse TCR α variable gene locus comprises a deletion selected from the group consisting of

(a) a deletion of all endogenous TCR Vα gene segments,

(b) a deletion of all endogenous TCR Jα gene segments, and

(c) a combination thereof, and/or

(II) an endogenous mouse TCR β variable gene locus comprises a deletion selected from the group consisting of

(a) a deletion of all endogenous TCR Vβ gene segments,

(b) a deletion of all endogenous TCR Dβ gene segments,

(c) a deletion of all endogenous TCR Jβ gene segments, and

(d) a combination thereof.

19. The mouse of claim 16 , wherein

(I) an endogenous mouse TCR α variable gene locus comprises a replacement selected from the group consisting of

(a) a replacement of at least one endogenous T cell variable region Vα gene segment with the at least one functional unrearranged human T cell variable region Vα gene segment,

(b) a replacement of at least one endogenous T cell variable region Jα gene segment with the at least one functional unrearranged human T cell variable region Jα gene segment, and

(c) a combination thereof, and/or

(II) an endogenous mouse TCR β variable gene locus comprises a replacement selected from the group consisting of

(a) a replacement of at least one endogenous T cell variable region Vβ gene segment with the at least one functional unrearranged human T cell variable region Vβ gene segment,

(b) a replacement of an endogenous T cell variable region Dβ1 gene segment with a functional unrearranged human T cell variable region Dβ1 gene segment, a replacement of an endogenous T cell variable region Dβ2 gene segment with a functional unrearranged human T cell variable region Dβ2 gene segment,

(c) a replacement of at least one endogenous T cell variable region Jβ1 gene segment with at least one functional unrearranged human T cell variable region Jβ1 gene segment, and a replacement of at least one endogenous T cell variable region Jβ2 gene segment with at least one functional unrearranged human T cell variable region Jβ2 gene segment, and

(d) a combination thereof.

20. The mouse of claim 16 , wherein:

(I) the unrearranged TCR α variable region sequence is positioned at an endogenous mouse TCR α variable gene locus such that the endogenous mouse TCR α variable gene locus comprises:

(a) a replacement of all endogenous T cell variable region Vα gene segments with all unrearranged human T cell variable region Vα gene segments from TRAV1-1 to TRAV41, and

(b) a replacement of all endogenous T cell variable region Jα gene segments with all unrearranged human T cell variable region Jα gene segments from TRAJ1 to TRAJ61; and

(II) the unrearranged TCR β variable region sequence is positioned at an endogenous mouse TCR β variable gene locus such that the endogenous mouse TCR β variable gene locus comprises:

(a) a replacement of all contiguous endogenous T cell variable region Vβ gene segments with all unrearranged human T cell variable region Vβ gene segments from TRBV1 to TRBV29-1,

(b)(i) a replacement of an endogenous tcrbdj1 cluster with a humanized TCRBDJ1 cluster comprising an unrearranged human TCRBD1 gene segment and (ii) each of an unrearranged human TCRBJ1-1 gene segment, an unrearranged human TCRBJ1-2 gene segment, an unrearranged human TCRBJ1-3 gene segment, an unrearranged human TCRBJ1-4 gene segment, an unrearranged human TCRBJ1-5 gene segment, and an unrearranged human TCRBJ1-6 gene segment,

wherein the humanized TCRBDJ1 cluster comprises a mouse TCRBDJ1 non-coding sequence between the unrearranged human TCRBD1 gene segment and the unrearranged human TCRBJ1-1 gene segment, and a mouse TCRBDJ1 non-coding sequence between any two consecutive unrearranged human TCRBJ1 gene segments, optionally wherein the unrearranged human TCRBD1 and TCRBJ1 gene segments flank the same mouse TCRBDJ1 non-coding sequences as are normally flanked by the corresponding mouse tcrbdj1 gene segments, and

(c)(i) a replacement of an endogenous tcrbdj2 cluster with a humanized TCRBDJ2 cluster comprising an unrearranged human TCRBD2 gene segment and (ii) each of an unrearranged human TCRBJ2-1 gene segment, an unrearranged human TCRBJ2-2 gene segment, an unrearranged human TCRBJ2-3 gene segment, an unrearranged human TCRBJ2-4 gene segment, an unrearranged human TCRBJ2-5 gene segment, an unrearranged human TCRBJ2-6 gene segment, and an unrearranged human TCRBJ2-7 gene segment,

wherein the humanized TCRBDJ2 cluster comprises a mouse TCRBDJ2 non-coding sequence between the unrearranged human TCRBD2 gene segment and any unrearranged human TCRBJ2 gene segment and a mouse TCRBDJ2 non-coding sequence between any two consecutive unrearranged human TCRBJ2 gene segments, optionally wherein the unrearranged human TCRBD2 and TCRBJ2 gene segments flank the same mouse TCRBDJ2 non-coding sequences as are normally flanked by the corresponding mouse tcrbdj2 gene segments.

21. The mouse of claim 20 , further comprising in its genome:

(a) a first nucleotide sequence encoding a chimeric human/mouse CD4 co-receptor that comprises D1, D2 and D3 domains of a human CD4 polypeptide operably linked to D4, transmembrane and cytoplasmic domains of a mouse CD4 polypeptide;

(b) a second nucleotide sequence encoding a chimeric human/mouse CD8α polypeptide and a third nucleotide sequence encoding a chimeric human/mouse CD8β polypeptide,

wherein the chimeric human/mouse CD8α polypeptide comprises an IgV-like domain of a human CD8α polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse CD8α polypeptide and wherein the chimeric human/mouse CD8β polypeptide comprises an IgV-like domain of a human CD8β polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse CD8β polypeptide;

(c) a fourth nucleotide sequence encoding a chimeric human/mouse MHC II a polypeptide and a fifth nucleotide sequence encoding a chimeric human/mouse MHC II B polypeptide,

wherein the chimeric human/mouse MHC II α polypeptide comprises α1 and α2 domains of a human HLA class II α polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse MHC II α polypeptide and wherein the chimeric human/mouse MHC II β polypeptide comprises β1 and β2 domains of a human HLA class II β polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse MHC II β polypeptide; and

(d) a sixth nucleotide sequence encoding a chimeric human/mouse MHC I polypeptide comprising α1, α2, and α3 domains of a human HLA class I polypeptide operably linked to transmembrane and cytoplasmic domains of a mouse MHC I polypeptide; and

(e) a β2 microglobulin locus encoding a human or humanized β2 microglobulin polypeptide.

22. The mouse of claim 21 , wherein the mouse expresses:

(A) the chimeric human/mouse CD4 co-receptor,

(B) a chimeric CD8 co-receptor comprising the chimeric human/mouse CD8α polypeptide and the chimeric human/mouse CD8β polypeptide,

(C) a chimeric MHC II complex comprising the chimeric human/mouse MHC II α polypeptide and the chimeric human/mouse MHC II β polypeptide, wherein the chimeric MHC II complex is capable of binding the chimeric human/mouse CD4 co-receptor,

(D) the chimeric human/mouse MHC I polypeptide, wherein the chimeric human/mouse MHC I polypeptide is capable of binding the chimeric CD8 co-receptor, and

(E) the human or humanized β2 microglobulin polypeptide.

23. The mouse of claim 16 , wherein at least 10% of TCRs expressed by the mouse is derived from gene segments from a TCRBDJ1 cluster and at least 10% of TCRs expressed by the mouse is derived from gene segments from a TCRBDJ2 cluster.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 12, 2025
From: GUO, CHUNGUANG; TU, NAXIN; MURPHY, ANDREW J.
To: REGENERON PHARMACEUTICALS, INC.
Reel/Frame 071401/0596 →
Continuity (2)
Provisional Application 63168774 · Mar 31, 2021
Related Publication 20220322648A1 · Oct 13, 2022
References Cited (400)
US 5175384A · Krimpenfort et al. · 1992 [cited by applicant]
US 5413923A · Kucherlapati et al. · 1995 [cited by applicant]
US 5416260A · Koller et al. · 1995 [cited by applicant]
US 5523226A · Wheeler et al. · 1996 [cited by applicant]
US 5574205A · Kucherlapati et al. · 1996 [cited by applicant]
US 5644065A · Benoist et al. · 1997 [cited by applicant]
US 5859312A · Littman et al. · 1999 [cited by applicant]
US 5942435A · Wheeler · 1999 [cited by applicant]
US 5958678A · Maddon et al. · 1999 [cited by applicant]
US 5965787A · Luthra et al. · 1999 [cited by applicant]
US 6002066A · Leung et al. · 1999 [cited by applicant]
US 6139835A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6270772B1 · Burrows et al. · 2001 [cited by applicant]
US 6372955B1 · Karlsson et al. · 2002 [cited by applicant]
US 6437216B1 · Duff et al. · 2002 [cited by applicant]
US 6514752B1 · Kucherlapati et al. · 2003 [cited by applicant]
US 6586251B2 · Economides et al. · 2003 [cited by applicant]
US 6596541B2 · Murphy et al. · 2003 [cited by applicant]
US 6815171B2 · Burrows et al. · 2004 [cited by applicant]
US 6982362B1 · Inoue et al. · 2006 [cited by applicant]
US 7105348B2 · Murphy et al. · 2006 [cited by applicant]
US 7265218B2 · Burrows et al. · 2007 [cited by applicant]
US 7294754B2 · Poueymirou et al. · 2007 [cited by applicant]
US 7339089B2 · Gotch · 2008 [cited by applicant]
US 7432414B2 · Chen et al. · 2008 [cited by applicant]
US 7462486B2 · Vandernbark · 2008 [cited by applicant]
US 7569664B2 · Jakobsen et al. · 2009 [cited by applicant]
US 7576259B2 · Poueymirou et al. · 2009 [cited by applicant]
US 7659442B2 · Poueymirou et al. · 2010 [cited by applicant]
US 7663017B2 · Lone et al. · 2010 [cited by applicant]
US 7745690B2 · Kanazawa et al. · 2010 [cited by applicant]
US 7763718B2 · Jakobsen et al. · 2010 [cited by applicant]
US 8084256B2 · Cai et al. · 2011 [cited by applicant]
US 8178653B2 · Tureci et al. · 2012 [cited by applicant]
US 8658854B2 · St-Arnaud · 2014 [cited by applicant]
US 8847005B2 · Macdonald et al. · 2014 [cited by applicant]
US 9043996B2 · Macdonald et al. · 2015 [cited by applicant]
US 9113616B2 · Macdonald et al. · 2015 [cited by applicant]
US 9585373B2 · Macdonald et al. · 2017 [cited by applicant]
US 9591835B2 · Macdonald et al. · 2017 [cited by applicant]
US 9615550B2 · Macdonald et al. · 2017 [cited by applicant]
US 9657311B2 · Bauche et al. · 2017 [cited by applicant]
US 9848587B2 · Macdonald et al. · 2017 [cited by applicant]
US 10154658B2 · Macdonald et al. · 2018 [cited by applicant]
US 10278373B2 · Harada et al. · 2019 [cited by applicant]
US 10793829B2 · Wabl · 2020 [cited by applicant]
US 10836832B2 · Green et al. · 2020 [cited by applicant]
US 10881084B2 · Wabl et al. · 2021 [cited by applicant]
US 11259510B2 · Macdonald · 2022 [cited by examiner]
US 20020164721A1 · Firat et al. · 2002 [cited by applicant]
US 20030093818A1 · Belmont et al. · 2003 [cited by applicant]
US 20030124524A1 · Kornman et al. · 2003 [cited by applicant]
US 20040137537A1 · Montero-Julian et al. · 2004 [cited by applicant]
US 20050050580A1 · Gotch et al. · 2005 [cited by applicant]
US 20050066375A1 · Thiam et al. · 2005 [cited by applicant]
US 20050114910A1 · Lone et al. · 2005 [cited by applicant]
US 20060015957A1 · Lonberg et al. · 2006 [cited by applicant]
US 20060107339A1 · Gotch et al. · 2006 [cited by applicant]
US 20070209083A1 · Thiam et al. · 2007 [cited by applicant]
US 20080152131A1 · Sendo et al. · 2008 [cited by applicant]
US 20080181899A1 · Papadopoulos et al. · 2008 [cited by applicant]
US 20080219947A1 · Linette et al. · 2008 [cited by applicant]
US 20090304657A1 · Morgan et al. · 2009 [cited by applicant]
US 20090328240A1 · Sing et al. · 2009 [cited by applicant]
US 20100011450A1 · Garcia et al. · 2010 [cited by applicant]
US 20100011452A1 · Tomizuka et al. · 2010 [cited by applicant]
US 20100111993A1 · Tureci et al. · 2010 [cited by applicant]
US 20100138938A1 · Garcia et al. · 2010 [cited by applicant]
US 20100175141A1 · Collins et al. · 2010 [cited by applicant]
US 20110067121A1 · Lone et al. · 2011 [cited by applicant]
US 20110158957A1 · Bonini et al. · 2011 [cited by applicant]
US 20110243995A1 · Voss et al. · 2011 [cited by applicant]
US 20130109053A1 · Macdonald et al. · 2013 [cited by applicant]
US 20130111617A1 · Macdonald et al. · 2013 [cited by applicant]
US 20130117873A1 · Wang et al. · 2013 [cited by applicant]
US 20130185819A1 · Macdonald et al. · 2013 [cited by applicant]
US 20140134662A1 · Flavell et al. · 2014 [cited by applicant]
US 20140245466A1 · Macdonald et al. · 2014 [cited by applicant]
US 20140245467A1 · Macdonald et al. · 2014 [cited by applicant]
US 20150040253A1 · Macdonald et al. · 2015 [cited by applicant]
US 20150245598A1 · Macdonald et al. · 2015 [cited by applicant]
US 20150342163A1 · Voronina et al. · 2015 [cited by applicant]
US 20160021856A1 · Macdonald et al. · 2016 [cited by applicant]
US 20170142944A1 · Macdonald et al. · 2017 [cited by applicant]
US 20170164590A1 · Macdonald et al. · 2017 [cited by applicant]
US 20170273286A1 · Macdonald et al. · 2017 [cited by applicant]
US 20170306352A1 · Wabl et al. · 2017 [cited by applicant]
US 20180139940A1 · Macdonald et al. · 2018 [cited by applicant]
US 20180288986A1 · Macdonald et al. · 2018 [cited by applicant]
US 20190223418A1 · Murphy · 2019 [cited by examiner]
US 20200375160A1 · Macdonald et al. · 2020 [cited by applicant]
US 20210068378A1 · Macdonald et al. · 2021 [cited by applicant]
CA 2471392A1 · 2003 [cited by applicant]
EP 0437576B1 · 2002 [cited by applicant]
EP 1878342A1 · 2008 [cited by applicant]
EP 1878798A1 · 2008 [cited by applicant]
EP 0950707B1 · 2009 [cited by applicant]
EP 1017721B1 · 2009 [cited by applicant]
EP 2275443A1 · 2011 [cited by applicant]
EP 1409646B1 · 2012 [cited by applicant]
EP 4059955A1 · 2022 [cited by applicant]
WO 1991001140A1 · 1991 [cited by applicant]
WO 1992011753A1 · 1992 [cited by applicant]
WO 1993005817A1 · 1993 [cited by applicant]
WO 1995003331A1 · 1995 [cited by applicant]
WO 1997032603A1 · 1997 [cited by applicant]
WO 1998024893A2 · 1998 [cited by applicant]
WO 2001027291A1 · 2001 [cited by applicant]
WO 2002059263A2 · 2002 [cited by applicant]
WO 2002066630A1 · 2002 [cited by applicant]
WO 2003006639A1 · 2003 [cited by applicant]
WO 2004042004A2 · 2004 [cited by applicant]
WO 2004083244A2 · 2004 [cited by applicant]
WO 2005004592A2 · 2005 [cited by applicant]
WO 2007131092A2 · 2007 [cited by applicant]
WO 2008010099A2 · 2008 [cited by applicant]
WO 2008010100A2 · 2008 [cited by applicant]
WO 2009125825A1 · 2009 [cited by applicant]
WO 2009114400A1 · 2009 [cited by applicant]
WO 2010039900A2 · 2010 [cited by applicant]
WO 2012071592A2 · 2010 [cited by applicant]
WO 20100107400A1 · 2010 [cited by applicant]
WO 20110004192A1 · 2011 [cited by applicant]
WO 20110039508A2 · 2011 [cited by applicant]
WO 2011044186A1 · 2011 [cited by applicant]
WO 2011097603A1 · 2011 [cited by applicant]
WO 2011100761A2 · 2011 [cited by applicant]
WO 2011111007A2 · 2011 [cited by applicant]
WO 2011123708A1 · 2011 [cited by applicant]
WO 2012007951A1 · 2012 [cited by applicant]
WO 2012039779A1 · 2012 [cited by applicant]
WO 2012018610A2 · 2012 [cited by applicant]
WO 2013063340A1 · 2013 [cited by applicant]
WO 2013063346A1 · 2013 [cited by applicant]
WO 2013063361A1 · 2013 [cited by applicant]
WO 2014130667A1 · 2014 [cited by applicant]
WO 2014130671A1 · 2014 [cited by applicant]
WO 2014164638A1 · 2014 [cited by applicant]
WO 2014164640A1 · 2014 [cited by applicant]
WO 2016164492A2 · 2016 [cited by applicant]
WO 2017210586A1 · 2017 [cited by applicant]
Janeway, C., Travers, P., Walport, M. and Shlomchik, M., 2001. Immunobiology: the immune system in health and disease (vol. 2, p. 154). New York: Garland Pub .. (Year: 2001). [cited by examiner]
Genbank Accession No. NP_741969.1 “T-cell surface glycoprotein CD8 alpha chain isoform 2 precursor [ [cited by applicant]
Genbank Accession No. AAB21668.2 “T cell surface glycoprotein CD8 beta 1 chain [ [cited by applicant]
Statement of Relatedness under MPEP 2001.06 with Respect to U.S. Appl. No. 17/709,150 dated Mar. 14, 2023. [cited by applicant]
Abarrategui and Krangel (2006) “Regulation of T cell receptor alpha gene recombination by transcription,” Nat. Immunol., 7:1109-1115 and Corrigendum. [cited by applicant]
Anderson (2008) “Post-transcriptional control of cytokine production,” Nature Immunology, 9(4):353-359. [cited by applicant]
Aggen et al. (2011) “Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors,” Protein Eng., Design & Selection, 24:361-372. [cited by applicant]
Allen et al. (1986) “B2-Microglobulin is not required for Cell surface expression of the murine class I histocompatibility antigen H-2Db or of a truncated H-2Db,” PNAS, 83:7447-7451. [cited by applicant]
Altmann et al. (1995) “The T Cell Response to HLA-DR Transgenic Mice to Human Myelin Basic Protein and other Antigens in the Presence and Absence of Human CD4,” J. Exp. Med., 181:867-875. [cited by applicant]
Alvarez et al. (1995) “V(D)J Recombination and Allelic Exclusion of a TCR B-Chain Minilocus Occurs in the Absence of a Functional Promoter,” J. Immunol., 155:1191-1202. [cited by applicant]
Arnold and Hammerling (1991) “MHC Class-1 Transgenic Mice,” Annu. Rev. Immunol., 9:297-322. [cited by applicant]
Auerbach et al. (2000) “Establishment and Chimera Analysis of 129/SvEV- and C57BL/6-Derived Mouse Embryonic Stem Cell Lines, ” BioTechniques, 29:1024-1032. [cited by applicant]
Baer, et al. (1986) “Organization of the T-Cell receptor alpha-chain gene and rearrangement in human T-Cell leukaemias,” Mol. Biol. Med., 3:265-277. [cited by applicant]
Baker et al. (1996) “Adaptation of TCR Expression Vectors for the Construction of Mouse-Human Chimeric MBP-Specific TCR Transgenes,” J. Neurosci. Research, 45:487-491. [cited by applicant]
Barber and Lechler (1991) “Interactions between the amino-terminal domains of MCH class II molecules have a profound effect on serologic and T cell recognition: an analysis using recombinant HLA-DR/H-2E molecules,” J. I… [cited by applicant]
Barnden, et al. (1988) “Defective TCR expression in transgenic mice constructed using cDNA-based alpha- and beta-chain genes under the control of heterologous regulatory elements,” Immunol. Cell Biol., 76:34-40. [cited by applicant]
Barthold (2004) “Genetically altered mice: phenotypes, no phenotypes, and Faux phenotypes,” Genetica, 122:75-88. [cited by applicant]
Basha et al. (2008) “MHC Class I Endosomal and Lysosomal Trafficking Coincides with Exogenous Antigen Loading in Dendritic cells,” PLoS ONE, 3:e3247, 11 pages. [cited by applicant]
Bassing et al. (2000) Recombination signal sequences restrict chromosomal V(D)J recombination beyond the 12/23 rule, Nature, 405:583-586. [cited by applicant]
Benmohamed et al. (2000)“ Induction of CTL Response by a Minimal Epitope Vaccine in HLA-A*0201/DR1 Transgenic Mice: Dependence on HLA Class II Restricted TH Response,” Hum. Immunol., 61:764-779. [cited by applicant]
Bernabeu et al. (1984) “B2-Microglobulin from serum associates with MHC class I antigens on the surface of cultured cells,” Nature, 308:642-645. [cited by applicant]
Beta-2 microglobulin https://en.wikipedia.org/w/index.php?title=Beta-2_microglobulin&oldid=452509865. [cited by applicant]
Betser-Cohen et al. (2010) “The Association of MHC Class I Proteins with the 2B4 Receptor Inhibits Self-Killing of Human NK cells,” J. Immunol., 184:2761-2768. [cited by applicant]
Bialer et al. (2010) “Selected Murine Residues Endow Human TCR with Enhanced Tumor Recognition,” J. Immunol., 184:6232-6241. [cited by applicant]
Bonnet, et al. (2009) “Molecular Genetics at the T-Cell Receptor B Locus: Insights into the Regulation of V(D)J Recombination,” V(D)J Recombination, 650:116-132. [cited by applicant]
Botten et al. (2007) “HLA-A2-Restricted Protection against Lethal Lymphocytic Choriomeningitis,” J. Virol. 81:2307-2317. [cited by applicant]
Bouffard et al. (1997) “A Physical Map of Human Chromosome 7: An Integrated YAC Contig Map with Average STS Spacing of 79 kb,” Genome Research, 7:673-692. [cited by applicant]
Boulter and Jakobsen (2005) “Stable, soluble, high-affinity, engineered T cell receptors: novel antibody-like proteins for specific targeting of peptide antigens,” Clin. Exp. Immunol., 142:454-460. [cited by applicant]
Boyd and Wood (2009) “Variation in MHC expression between undifferentiated mouse ES cells and ES cell derived insulin-producing cell clusters,” Transplantation, 87(9):1300-1304. [cited by applicant]
Brehm et al. (2010) “Humanized Mouse Models to Study Human Diseases,” Curr. Opin. Endocrinol. Diabetes Obes., 17:120-125. [cited by applicant]
Brevini et al. (2010) “Embryonic Stem Cells in Domestic Animals; No shortcuts to pig embryonic stem cells,” Theriogenology, 74:544-550. [cited by applicant]
Brouwers et al. (2015) “Unexpected Phenotypes in Mouse Models Carrying the Human Growth Hormone Minigene to Enhance Transgene Expression,” Journal of Steroids & Hormonal Science, 6(2):1000.e115 (2 pages). [cited by applicant]
Brusko et al. (2010) “Human Antigen-Specific Regulatory T cells Generated by T cell receptor Gene Transfer,” PLoS ONE, 5:e11726, 12 pages. [cited by applicant]
Buta et al. (2013) “Reconsidering pluripotency tests: Do we still need teratoma assays?,” Stem Cell Res., 11:552-562. [cited by applicant]
Call and Wucherpfennig (2005) “The T cell receptor: Critical Role of the Membrane Environment in Receptor Assembly and Function,” Annu. Rev. Immunol., 23:101-125. [cited by applicant]
Cameron, E. (1997) “Recent Advances in Transgenic Technology,” Molecular Biotechnology, 7:253-265. [cited by applicant]
Campbell (1997) “Totipotency or Multipotentiality of Cultured cells: Applications and Progress,” Theriogenology, 47:(1), 63-72. [cited by applicant]
Cao et al., (2009) “Isolation and Culture of Primary Bovine Embryonic Stem Cell Colonies by a Novel Method,” Journal of Experimental Zoology, 311A:368-376. [cited by applicant]
Capone, et al. (1995) “T Cell Development in TCR-alphabeta Transgenic Mice Analysis using V(D)J Recombination Substrates,” J. Immunol., 5165-5172. [cited by applicant]
Carpenter, et al. (2014) “Post-transcriptional regulation of gene expression in innate immunity,” Nature Reviews Immunology, 14:361-376. [cited by applicant]
Carrasco et al. (2003) “A role for the cytoplasmic tail of the pre-T cell receptor (TCR) alpha chain in promoting constitutive internalization and degradation of the pre-TCR,” J. Biol. Chem., 278:14507-13. [cited by applicant]
Carstea et al. (2009) “Germline competence of mouse ES and iPS Cell lines: Chimera technologies and genetic background,” World Journals of Stem Cells, 1(1):22-29. [cited by applicant]
Chamberlain et al. (1988)“Tissue-specific and Cell surface expression of human major histocompatibility complex class I heavy (HLA-B7) and light (B2-microglobulin) chain genes in transgenic mice,” PNAS, 86:7690-7694. [cited by applicant]
Cheuk et al. “Human MHC Class I Transgenic Mice Deficient for H2 Class I Expression Facilitate Identification and Characterization of New HLA Class I-Restricted Viral T Cell Epitopes,” Journal of Immunology, 2002, 169:5… [cited by applicant]
Chhabra (2011) “TCR-Engineered, Customized, Antitumor T cells for Cancer Immunotherapy: Advantages and Limitations,” The Scientific World J., 11:121-129. [cited by applicant]
Choi et al., (2011) “Expression of the metabotropic glutamate receptor 5 (mGluR5) induces melanoma in transgenic mice,” PNAS, 108(37):1519-15224. [cited by applicant]
Chung et al. (1994) “Functional three-domain single-chain T-Cell receptors,” PNAS, 91:12654-12658. [cited by applicant]
Clark et al. (1987) “Peptide and nucleotide sequences of rat CD4 (W3/25) antigen: evidence for derivation from a structure with four immunoglobulin-related domains,” PNAS, 84(6):1649-1653. [cited by applicant]
Cohen, et al. (2006) “Enhanced Antitumor Activity of Murine-Human Hybrid T-Cell Receptor (TCR) in Human Lymphocytes is Associated with Improved Pairing and TCR/CD3 Stability,” Cancer Res., 66:8878-8886. [cited by applicant]
Connolly et al. (1988) “The Lyt-2 Molecule Recognizes Residues in the Class I alpha3 Domain in Allogeneic Cytotoxic T Cell Responses,” J. Exp. Med., 168:325-341. [cited by applicant]
Cooper et al. (2007) “An Impaired Breeding Phenotype in Mice with a Genetic Deletion of Beta-2 Microglobulin and Diminished MHC Class I Expression: Role in Reproductive Fitness,” Biol. Reprod., 77:274-279. [cited by applicant]
Corbeil et al. (1996) “HIV-induced Apoptosis Requires the CD4 Receptor Cytoplasmic Tail and Is Accelerated by Interaction of CD4 with p56lck,” J. Exp. Med., 183:39-48. [cited by applicant]
Cosson and Bonifacino (1992) “Role of Transmembrane Domain Interactions in the Assembly of Class II MHC Molecules,” Science, 258:659-662. [cited by applicant]
Crusio (2004) “Flanking Gene and Genetic Background Problems in Genetically Manipulated Mice,” Biol. Psychiatry, 56:381-385. [cited by applicant]
Daniel-Meshulam et al. (2012) “How (specific) would you like your T-cells today? Generating T-Cell therapeutic function through TCR-gene transfer,” Front. Immunol., 3:186, 13 pages. [cited by applicant]
Danner et al. (2011) “Expression of HLA Class II Molecules in Humanized NOD.Rag1KO.IL2RgcKO Mice is Critical for Development and Function of Human T and B cells,” PLoS ONE, 6:e19826, 12 pages. [cited by applicant]
Database entry for Ncb I Reference Sequence: NG 001333.2 (Sep. 19, 2006) “Homo sapiens T cell receptor beta locus (TRB) on chromosome 7”. [cited by applicant]
De Bakker et al. (2006) “A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC,” Nature Genet. Online Supplement, 33 pages. [cited by applicant]
De Bakker et al. (2006) “A high-resolution HLA and SNP haplotype map for disease association studies in the extended human MHC,” Nature Genet., 38:1166-1172. [cited by applicant]
De Gassart et al. (2008) “MHC class II stabilization at the surface of human dendritic cells is the result of maturation-dependent March I down-regulation,” PNAS, 105:3491-3496. [cited by applicant]
Dennis (2002) “Welfare issues of genetically modified animals,” ILAR Journal, 43(2):100-109. [cited by applicant]
Dietrich et al. (2003) “Prevalent Role of TCR alpha-chain in the Selection of the Preimmune Repertoire Specific for a Human Tumor-Associated Self-Antigen,” J. Immunol., 170:5103-5109. [cited by applicant]
Doetschman (2009) “Influence of Genetic Background on Genetically Engineered Mouse Phenotypes,” Methods Mol. Biol., 530:423-433. [cited by applicant]
Dolan et al. (2004) “Invariant Chain and the MHC Class II Cytoplasmic Domains Regulate Localization of MHC Class II Molecules to Lipid Rafts in Tumor Cell-Based Vaccines,” J. Immunol., 172:907-914. [cited by applicant]
Duke (1989) “Self-Recognition by T Cell,” J. Exp. Med. 170:59-71. [cited by applicant]
Dupic et al. (Mar. 4, 2019) “Genesis of the αβ T-cell receptor,” PLOS Computational Biology, 15(3):e1006874, pp. 1-19. [cited by applicant]
El Fakhry et al. (2004) “Delineation of the HLA-DR Region and the Residues Involved in the Association with the Cytoskeleton,” J. Biol. Chem., 279:18472-18480. [cited by applicant]
Ellmeier et al. (1998) “Multiple developmental stage-specific enhancers regulate CD8 expression in developing thymocytes and in thymus-independent T cells,” Immunity, 9(4):485-496. [cited by applicant]
Epel et al. (2002) “A functional recombinant single-chain T cell receptor fragment capable of selectively targeting antigen-presenting cells,” Cancer Immunol. Immunother., 51:565-573. [cited by applicant]
Epstein et al. “Expression and function of HLA-A2.1 in transgenic mice,” Eur. J. Immunol., 1989, 19:1575-1583. [cited by applicant]
Ferrier et al. (1990) “Separate elements control DJ and VDJ rearrangement in a transgenic recombination substrate,” EMBO J., 9:117-125. [cited by applicant]
Festing et al. (1999) “Revised nomenclature for strain 129 mice,” Mamm. Genome, 10:836. [cited by applicant]
Firat et al. (2002) “Comparative analysis of the CD8+ T Cell repertoires of H-2 class I wild-type/HLA-2.1 and H-2 class I knockout/HLA-A2.1 transgenic mice,” Internal. Immunol., 14:925-934. [cited by applicant]
Fleischer et al. (1996) Reactivity of Mouse T-Cell Hybridomas Expressing Human VB Gene Segments with Staphylococcal and Streptococcal Superantigens, Infection and Immunity, 64(3):987-994. [cited by applicant]
Fooksman et al. (2009) “Cutting Edge: Phospholidylinositol 4, 5-Bisphosphate Concentration at the APC Side of the Immunological Synapse Is Required for Effector T Cell Function,” J. Immunol., 182:5179-5182. [cited by applicant]
Friese et al. (2006) “Humanized mouse models for organ-specific autoimmune diseases,” Curr. Opin. Immunol., 18:704-709. [cited by applicant]
Friese et al., (2008) “Opposing effects of HLA class I molecules in tuning autoreactive CD8+ T cells in multiple scelerosis,” Nature Med., 14(11): 1227-1235. [cited by applicant]
Fugger et al. (1994) “Expression of HLA-DR4 and human CD4 transgenes in mice determines the variable region beta-chain T-Cell repertoire and mediates an HLA-DR-restricted immune response,” PNAS, 91:6151-6155. [cited by applicant]
Fukui et al. (1993) “T-cell repertoire in a strain of transgenic C57BL/6 mice with the HLA-DRA gene on the X-chromosome,” Immunogenetics, 37(3):204-211. [cited by applicant]
Fukui et al. (1997) “Differential requirement of MHC class II molecules expressed on hematopoietic cells for positive selection of CD4+ thymocytes in TCR a ß and TCR α β transgenic mice,” Internal. Immunol., 9(9):1385-1… [cited by applicant]
Gao et al. (1997) “Crystal structure of the complex between human CD8alpha-alpha and HLA-A2,” Nature, 387:630-634. [cited by applicant]
Gao et al. (2000) “Molecular interactions of coreceptor CD8 and MHC class 1: the molecular basis for functional coordination with the T-Cell receptor,” Immunol. Today, 21 (12):630-636. [cited by applicant]
GE and Stanley (2008) “The O-fucose glycan in the ligand-binding domain of Notch 1 regulates embryogenesis and T Cell development,” PNAS, 105:1539-1544. [cited by applicant]
Germain (2002) “T-Cell Development and The CD4-CD8 Lineage Decision, Nature Reviews, Immunol.,” 2:309-322. [cited by applicant]
Giraldo and Montoliu (2001) “Size matters: use of YACs, BACs and PACs in transgenic animals,” Transgenic Research, 10:83-103. [cited by applicant]
Glick and pasternak Dzh. Moleculyarnaya biotehnologiya. Printsipy i primeneniye. Moscow: Mir, 2002 (with English translation). [cited by applicant]
Glusman et al. (2001) “Comparative Genomics of the Human and Mouse T Cell Receptor Loci,” Immunity, 15:337-349. [cited by applicant]
Godfrey et al. (1993) “Control Points in early T-Cell development,” Immunol. Today, 14:547-553. [cited by applicant]
Goldman et al. (2004) “Transgenic animals in medicine: Integration and expression of foreign genes, theoretical and applied aspects,” Med. Sci. Monit., 10(11): RA274-285. [cited by applicant]
Gomez et al. (2010) “Derivation of cat embryonic stem-like cells from in vitro-produced blastocysts on homologous and heterologous feeder cells,” Theriogenology, 74:498-515. [cited by applicant]
Gonnet et al. (1992) Exhaustive Matching of the Entire Protein Sequence Database, Science 256:1443-1445. [cited by applicant]
Gruda et al. (2007) “Intracellular Cysteine Residues in the Tail of MHC Class I Proteins Are Crucial for Extracellular Recognition by Leukocyte Ig-Like Receptor 1,” J. Immunol., 179:3655-3661. [cited by applicant]
Gudipaty et al. “Mechanical stretch triggers rapid epithelial cell division through Piezo1,” Nature, Mar. 2017, 543:118-129. [cited by applicant]
Günther and Walter (2001) “The major histocompatibility complex of the rat ( [cited by applicant]
Gur et al. (1997) “Structural Analysis of Class I MHC Molecules: The Cytoplasmic Domain Is Not Required for Cytoskeletal Association, Aggregation and Internalization,” Mol. Immunol., 34:125-132. [cited by applicant]
GüSsow et al. (1987) “The Human B2-Microglobulin Gene. Primary Structure and Definition of the Transcriptional Unit,” J. Immunol., 139:3132-3138. [cited by applicant]
Haks et al. (1999) “Cell-fate decisions in early T cell development: regulation by cytokine receptors and the pre-TCR,” Immunol., 11:23-37. [cited by applicant]
Hall (2008) “Porcine Embryonic Stem Cells: A Possible Source for Cell Replacement Therapy,” Stem Cell Rev., 4:275-282. [cited by applicant]
Hammer et al. (1990) “Spontaneous Inflammatory Discease in Transgenic Rats Expressing HLA-B27 and Human β [cited by applicant]
Hanna et al. (1994) “Specific expression of the human CD4 gene in mature CD4 + CD8- and immature CD4+ CD8+ T cells and in macrophages of transgenic mice,” Mol. Cellular Biol., 14(2):1084-1094. [cited by applicant]
Harari et al., “Bridging the Species Divide: Transgenic Mice Humanized for Type-I Interferon Response,” PLOS One, Jan. 2014, 9(1):e84259, 12 pages. [cited by applicant]
Harton et al. (2016) “Immunological Functions of the Membrane Proximal Region of MHC Class II Molecules,” F1000Research, 5:1-12, doi: 10.12688/f1000research.7610.1. [cited by applicant]
Holdsworth et al. (2009) “The HLA dictionary 2008: a summary of Hla-A, -B, -C-DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -Dr, and -DO antigens,” Tissue Antigens, 73:95-… [cited by applicant]
Holst, et al. (2006) “Generation of T-Cell receptor retrogenic mice,” Nat. Protoc., 1:406-417. [cited by applicant]
Hong et al. (2012) “Derivation and Characterization of Embryonic Stem Cells Lines Derived from Transgenic Fischer 344 and Dark Agouti Rats,” Stem Cells and Development, 21(9):1571-1586. [cited by applicant]
Hostert et al. (1997) “A CD8 genomic fragment that directs subset-specific expression of CD8 in transgenic mice,” J. Immunol., 158(9):4270-4281. [cited by applicant]
Hou et al. (2016) “Derivation of Porcine Embryonic Stem-Like Cells from In Vitro-Produced Blastocyst-Stage Embryos,” Scientific Research, 6:1-13. [cited by applicant]
Houdebine (1994) “Production of pharmaceutical proteins from transgenic animals,” J. Biotechnology, 34:269-287. [cited by applicant]
Houdebine (2002) “The methods to generate transgenic animals and to control transgene expression,” J. of Biotech., 98:145-160. [cited by applicant]
Houdebine (2007) “Transgenic Animal Models in Biomedical Research,” Methods in Molecular Biology, 360:163-202. [cited by applicant]
Houdebine (2009) “Methods to Generate Transgenic Animals,” Genetic Engineering in Livestock, New Applications and Interdisciplinary Perspectives, Engelhard M, et al., 2009, XVI, 1 46 p. 8 illus., pp. 31-48, see p. 36. [cited by applicant]
Huang et al. (1997) “Analysis of the contact sites on the CD4 Molecule with Class II MHC Molecule,” J. Immunol., 158:215-225. [cited by applicant]
Intarapat and Stern (2013) “Chick stem cells: Current progress and future prospects,” Stem Cell Res., 11:1378-1392. [cited by applicant]
International Mhc and Autoimmunity Genetics Network (Imagen) (2009) “Mapping of multiple susceptibility variants within the MHC region for 7 immune-mediated diseases,” PNAS, 1 06: 18680-18685. [cited by applicant]
Irie et al. (1998) “The cytoplasmic domain of CD8 beta regulates Lck kinase activation and CD8 T cell development,” J. Immunol., 161(1):183-191. [cited by applicant]
Irwin et al. (1989) “Species-restricted interactions between CD8 and the alpha3 domain of class I influence the magnitude of the xenogeneic response,” J. Exp. Med., 170:1091-1101. [cited by applicant]
Ishimoto et al. (1997) “In vitro and in vivo evidence for high frequency of I-Ab-reactive CD4+ T cells in HLA-DQ or HLA-DRA transgenic mice lacking endogenous MHC class I and/or class II expression,” J. Immunol., 159(8)… [cited by applicant]
Itano et al. (1996) “The Cytoplasmic Domain of CD4 Promotes the Development of CD4 Lineage T Cells,” J. Exp. Med., 183(3):731-741. [cited by applicant]
Ito et al. (1996) “HLA-DR4-IE Chimeric Class II Transgenic, Murine Class II-Deficient Mice Are Susceptible to Experimental Allergic Encephalomyelitis,” J. Exp. Med., 183:2635-2644. [cited by applicant]
Jakobovits (1994) “Humanizing the mouse genome,” Cur. Biol., 4(8):761-763. [cited by applicant]
Janeway's Immunobiology, 7th Ed., Murphy et al. eds., Garland Science, 2008. [cited by applicant]
Jean et al. (2013) “Pluripotent genes in avian stem cells,” Develop. Growth Differ., 55:41-51. [cited by applicant]
Johansson et al. (2005) “Natural killer Cell education in mice with single or multiple major histocompatibility complex class I molecules,” J. Exp. Med., 201:1145-1155. [cited by applicant]
Johnson et al. (1987) “A human homolog of the mouse CD8 molecule, Lyt-3: genomic sequence and expression,” Immunogenetics, 26(3):174-177. [cited by applicant]
Johnson et al. (2009) “Gene therapy with human and mouse T-Cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen,” Blood, 114:535-546. [cited by applicant]
Josson et al. (2011) “B2 microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells,” Cancer Res., 71:1-11. [cited by applicant]
Kalinke et al. (1990) “Strong Xenogeneic HLA Response in Transgenic Mice after Introducing an Alpha3 Domain into HLA B27,” Nature, 348:642-644. [cited by applicant]
Kaplan et al. (2005) “A new murine tumor model for studying HLA-A2-restricted anti-tumor immunity,” Cancer Letters, 224:153-166. [cited by applicant]
Kappel et al. (1992) “Regulating gene expression in transgenic animals,” Current Opinion in Biotechnology, 3:548-553. [cited by applicant]
Kawamata and ochiya (2010) “Generation of genetically modified rats from embryonic stem cells,” PNAS, 107(32):14223-14228. [cited by applicant]
Kawamura et al. (2008) “Different Development of Myelin Basic Protein Agonist- and Antagonist-Specific Human TCR Transgenic T Cells in the Thymus and Periphery,” J. Immunol., 181(8):5462-5472. [cited by applicant]
Khor et al. (2002) “Allelic exclusion at the TCRβ locus,” Curr. Opin. Immunol., 14:230-234. [cited by applicant]
Kievits et al. (1987) “HLA-restricted recognition of viral antigens in HLA transgenic mice,” Nature 329:447-449. [cited by applicant]
Killeen et al. (1993) “Regulated expression of human CD4 rescues helper T cell development in mice lacking expression of endogenous CD4,” EMBO J., 12(4): 1547-1553. [cited by applicant]
Kioussis et al. (2002) “Chromatin and CD4, CD8A and CD8B gene expression during thymic differentiation,” Nature Rev. Immunol., 2(12):909-919. [cited by applicant]
Kirwan et al. (2005) “Killer Cell Ig-Like Receptor-Dependent Signaling by ig-Like Transcript 2 (ILT2/CD85j/LILRB1/ LIR-1),” J. Immunol., 175:5006-5015. [cited by applicant]
Koller and orr (1985) “Cloning and complete sequence of an HLA-A2 gene: Analysis of two HLA-A Alleles at the nucleotide Level” J. Immunol. 134(4):2727-2733. [cited by applicant]
Koller et al. (1990) “Normal Development of Mice Deficient in B2M, MHC Class I Proteins, and CD8+ T cells,” Science, 248:1227-1230. [cited by applicant]
Koop et al., (1994) “The human T-cell receptor Tcrac/Tcrdc (C alpha/C delta) region: organization, sequence, and evolution of 97.6 kb of DNA,” Genomics 19(3):478-493. [cited by applicant]
Kouskoff et al. (1995) “Cassette vectors directing expression of T cell receptor genes in transgenic mice,” J. Immunol. Methods, 180:273-280. [cited by applicant]
Krangel et al. (1998) “Development regulation of V(D)J recombination at the TCR α/δ locus,” Immunol. Rev., 165:131-147. [cited by applicant]
Kruisbeek et al., (2000) “Branching out to gain control: how the pre-TCR is linked to multiple functions,” Rev. Immunol. Today, 21 (12):637-644. [cited by applicant]
Kuhns et al. (2006) “Deconstructing the Form and Function of the TCR/CD3 Complex,” Immunity, 24:133-139. [cited by applicant]
Kuhns and Davis “TCR signaling emerges from the sum of many parts,” Frontiers in Immunology, 3:1-13 (2012). [cited by applicant]
Kumanovics et al. (2003) “Genomic Organization of the Mammalian MHC,” Annu. Rev. Immunol., 21:629-657. [cited by applicant]
Laface et al. (1995) “Human CD8 Transgene Regulation of HLA Recognition by Murine T cells,” J. Exp. Med., 182:1315-1325. [cited by applicant]
Lalor et al. (1992) “Molecular cloning, reconstruction and expression of the gene encoding the alpha-chain of the bovine CD8-definition of three peptide regions conserved across species,” Immunology, 76:95-102. [cited by applicant]
Landau et al. (1988) “The envelope glycoprotein of the human immunodeficiency virus binds to the immunoglobulin-like domain of CD4,” Nature, 334(6178): 159-162. [cited by applicant]
Laub et al. (2000) “A multiple transgenic mouse model with a partially humanized activation pathway for helper T cell responses,” J. Immunol. Methods, 246(1-2):37-50. [cited by applicant]
Lauzurica et al. (1994) “Temporal and Lineage-specific control of T cell receptor alpha/delta gene rearrangement by T Cell, receptor alpha and delta enhancers,” J. Exp. Med., 179:1913-1921. [cited by applicant]
Lauzurica P. and Krangel M.S. (1994) “Enhancer-dependent and -independent Steps in the Rearrangement of a Human T Cell Receptor Delta Transgene,” J. Exp. Med., 179:43-55. [cited by applicant]
Lavial et al., (2008) “Molecular control of pluripotency and germ line competency in chicken embryonic stem cells,” Cell Research, 18:s106 (1 page). [cited by applicant]
Lavial and pain (2010) “Chicken embryonic stem cells as a non-mammalian embryonic stem cell model,” Develop. Growth Differ., 52:101-114. [cited by applicant]
Law et al. (1994) “Human CD4 Restores Normal T Cell Development and Function in Mice Deficient in Murine CD4,” J. Exp. Med., 179(4): 1233-1242. [cited by applicant]
Leahy (1995) “A structural view of CD4 and CD8,” Faseb J., 9:17-25. [cited by applicant]
Leduc et al. (2000) “T Cell Development in TCRβ Enhancer-Deleted Mice: Implications for αβ T Cell Lineage Commitment and Differentiation,” J. Immunol., 165:1364-1373. [cited by applicant]
Lee et al. (1982) “Sequence of an HLA-DR alpha-chain cDNA clone and intron-exon organization of the corresponding gene,” Nature, 299:750-752. [cited by applicant]
Lefranc, M. (2003) “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Research, 31(1):307-310. [cited by applicant]
Li et al. (2009) “Mamu-A*01/Kb transgenic and MHC Class I knockout mice as a tool for HIV vaccine development,” Virology, 387:16-28. [cited by applicant]
Li et al. (2010) “Transgenic mice with a diverse human T Cell antigen receptor repertoire,” Nature Med., 16(9):1029-1034, doi:10.1038/nm.2197. [cited by applicant]
Li et al. (2010) “Transgenic mice with a diverse human T Cell antigen receptor repertoire,” Nature Med., 16, supplementary materials, 22 pages. [cited by applicant]
Li et al. (2013) “Generation of transgenic mice with megabase-sized human yeast artificial chromosomes by yeast spheroplast-embryonic stem cell fusion,” Nat. Protoc., 8(8):1567-1582, doi:10.1038/nprot.2013.093. [cited by applicant]
Li et al. (2016) “The Implication and Significance of Beta 2 Microglobulin: A Conservative Multifunctional Regulator,” Chinese Medical Journal, 129(4):448-455. [cited by applicant]
Lie and petropoulos (1998) “Advances in quantitative PCR technology: 5′ nuclease assays,” Curr. Opin. Biotech., 9:43-48. [cited by applicant]
Linder C. (2006) “Genetic Variables That Influence Phenotype,” ILAR Journal, 47(2):132-140. [cited by applicant]
Linnemann et al. (2011) “T-Cell Receptor Gene Therapy: Critical Parameters for Clinical Success,” J. Invest. Dermalol., 131:1806-1816. [cited by applicant]
Linnenbach et al. (1980) “DNA-transformed murine teratocarcinoma cells: regulation of expression of simian virus 40 tumor antigen in stem versus differentiated cells,” PNAS, 77(8):4875-4879. [cited by applicant]
Littman (1987) “The Structure of the CD4 and CD8 Genes,” Annual Review of Immunology, 5:561-584. [cited by applicant]
Lizee et al. (2003) “Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain,” Nature Immunol., 4:1065-1073. [cited by applicant]
Love and hayes (2010) “ITAM-Mediated Signaling by the T-Cell Antigen Receptor,” Cold Spring Harb. Perspec. Biol., 2:e002485. [cited by applicant]
Lynch et al. (2009) “Novel MHC Class I Structures on Exosomes,” J. Immunol., 183:1884-1891. [cited by applicant]
Mackay (1999) “Dual personality of memory T cells,” Nature, 401:659-660. [cited by applicant]
Maddon et al. (1987) “Structure and expression of the human and mouse T4 genes,” PNAS, 84(24):9155-9159. [cited by applicant]
Madsen et al. (1999) “A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor,” Nature Genet., 23:343-347. [cited by applicant]
Magliocca et al. (2006) “Undifferentiated Murine Embryonic Stem Cells Cannot Induce Portal Tolerance but May Possess Immune Privilege Secondary to Reduced Major Histocompatibility Complex Antigen Expression,” Stem Cells… [cited by applicant]
Maksimenko et al. (2013) “Use of Transgenic Animals in Biotechnology: Prospects and Problems,” ACTA Naturae, 5(1):33-46. [cited by applicant]
Mantovani et al. (2002) Dominant TCR-alpha Requirements for a Self Antigen Recognition in Humans, J. Immunol., 169:6253-6260. [cited by applicant]
Manz et al. (2009) “Renaissance for mouse models of human hematopoiesis and immunobiology,” Nature Immunology, 10(10):1039-1042. [cited by applicant]
Marsh et al. (2010) “Nomenclature for factors of the HLA system,” 2010, Tissue Antigens, 75:291-455. [cited by applicant]
Marten Hofker et al. (2003) “Transgenic mouse methods and protocols,” Methods in Molecular Biology, 209:51-58. [cited by applicant]
Massimo et al. (2008) “Primer: Immunity and Autoimmunity,” Diabetes, 57(11):2872-2882. [cited by applicant]
Matloubian et al. (1994) “CD4+ T cells are required to sustain CD8+ cytotoxic T-cell responses during chronic viral infection,” J. Virol., 68(12):8056-8063. [cited by applicant]
McMurry et al. (1997) “Enhancer Control of Local Accessibility to V(D)J Recombinase,” Molecular and Cellular Biology, 17(8):4553-4561. [cited by applicant]
Mendez et al. (1997) “Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice,” Nature Genet., 15(2):146-156. [cited by applicant]
Miao (2012) “Recent Advances and Applications of Transgenic Animal Technology,” Polymerase Chain Reaction, Dr. Patricia Hernandez-Rodriguez (Ed.), ISBN: 978-953-51-0612-8, InTech, pp. 255-282, Available from: http://www… [cited by applicant]
Moir et al. (1996) “Postbinding events mediated by human immunodeficiency virus type 1 are sensitive to modifications in the D4-transmembrane linker region of CD4,” J. Virology, 70(11) :8019-8028. [cited by applicant]
Moldovan et al. (2002) “CD4 Dimers Constitute the Functional Component Required forT Cell Activation,” J. Immunol., 169:6261-6268. [cited by applicant]
Mombaerts P. et al. (1991) “Creation of a large genomic deletion at the T-cell antigen receptor B-subunit locus in mouse embryonic stem cells by gene targeting,” PNAS, 88:3084-3087. [cited by applicant]
Mombaerts et al. (1992) “Mutations in T-cell antigen receptor genes a and B block thymocyte development at different stages,” Nature, 360:225-231. [cited by applicant]
Mombaerts et al. (1993) “Spontaneous Development of Inflammatory Bowel Disease in T Cell Receptor Mutant Mice,” Cell, 75:275-282. [cited by applicant]
Moore et al. (2021) “Humanization of T cell-mediated immunity in mice,” Science Immunology, 6(eabj4026) 12 pages, and Supplemental Materials, 20 pages (32 pages total). [cited by applicant]
Morgan et al. (2006) “Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes,” Science, 314:126-129. [cited by applicant]
Munoz et al. (2008) “Technical note; Conventional pluripotency markers are unspecific for bovine embryonic-derived cell-lines,” Theriogenology, 69:1159-1164. [cited by applicant]
Declaration from Dr. Andrew Murphy regarding Mar. 1, 2007 meeting (81 pages), which includes the following Exhibits: Exhibit A: Agenda for meeting between “Regeneron and a Whole Bunch of Interested Academics” re “The Hu… [cited by applicant]
Murphy, K., Travers, P., Walport, M., & Janeway, C. (2008) Janeway's Immunobiology. New York: Garland Science, 2008, at pp. 156-157. [cited by applicant]
Murphy et al. (2008) “Janeway's Immunobiology” 7th ed., Garland Science, pp. 125-13B and 196-213. [cited by applicant]
Murphy and silha (2000) “Unexpected and unexplained phenotypes in transgenic models,” Growth Hormone & IGF Research, 10:233-235. [cited by applicant]
Musser G. (Encyclopedia Britannica, May 31, 2016) Rodent, Mammal, http://www.britannica.com/animal/rodent. [cited by applicant]
Nakayama et al. (1989) “Structure and expression of the gene encoding CD8α chain (Leu-2/T8),” Immunogenetics, 30:393-397. [cited by applicant]
Nakayama et al. (1992) “Recent Duplication of the Two Human CD8 β-chain genes,” J. Immunol., 148:1919-1927. [cited by applicant]
NCBI Accession No. NG_001332.2 (2012) “Homo sapiens T cell receptor alpha delta locus (TCRA/TCRD) on chromosome 14,” NCBI, 2 pages. [cited by applicant]
Newberg et al. (1992) “Species specificity in the interaction of CD8 with the alpha 3 domain of MHC class I molecules,” J. Immunol., 149(1):136-142 Abstract. [cited by applicant]
Newberg et al. “Importance of MHC class I alpha2 and alpha3 domains in the recognition of self and non-self MHC molecules,” Journal of Immunology, 1996, 156:2473-2480. [cited by applicant]
Nickerson et al. (1990) “Expression of HLA-B27 in Transgenic Mice Is Dependent on the Mouse H-20 Genes,” J. Exp. Med., 172:1255-1261. [cited by applicant]
Noordzij et al. (2000) “N-terminal truncated human RAG1 proteins can direct T-cell receptor but not immunoglobulin gene rearrangements,” Blood, 96(1):203-209. [cited by applicant]
Norment et al. (1988) “A second subunit of CD8 is expressed in human T cells,” Embo J., 7(11):3433-3439. [cited by applicant]
Norment et al. (1989) “Alternatively Spliced mRNA Encodes a Secreted Form of Human CD8a, Characterization of the Human CD8a gene,” J. Immunol., 142:3312-3319. [cited by applicant]
Nowak et al. (1992) “The optimal No. of major histocompatibility complex molecules in an individual,” Immunology, 89:10896-10899. [cited by applicant]
Ostrand-Rosenberg et al. (1991) “Abrogation of Tumorigenicity by MHC Class II Antigen Expression Requires the Cytoplasmic Domain of the Class II Molecule,” J. Immunol., 147:2419-2422. [cited by applicant]
Pajot et al. (2004) “A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice,” Eur. J. Immunol., 34:3060-3069. [cited by applicant]
Paris and stout (2010) “Embryonic Stem Cells in Domestic Animals; Equine embryos and ebryonic stem cells: Defining reliable markers of pluripotency,” Theriogenology, 74:516-524. [cited by applicant]
Parnes, et al. (1982) “Structure of Wild-Type and Mutant Mouse β [cited by applicant]
Pasare et al. (2001) “T cells in mice expressing a transgenic human TCRβ chain get positively selected but cannot be activated in the periphery by signaling through TCR,” Intl. Immunol., 13(1):53-62. [cited by applicant]
Pascolo (1997) “HLA-A2.1-restricted Education and Cytolytic Activity of CD8+ T Lymphocytes from β [cited by applicant]
Pascolo, et al. (2005) “HLA class I transgenic mice: development, utilisation and improvement,” Expert Opinion Biol. Ther., 5(7):919-938. [cited by applicant]
Perarnau et al. (1988) “Human B2-microglobulin specifically enhances cell-surface expression of HLA class I molecules in transfected murine cells,” J. Immunol., 141:1383-1389. [cited by applicant]
Petitte et al. (2004) “Avian pluripotent stem cells,” Mechanisms of Development, 121:1159-1168. [cited by applicant]
Pettersen et al. (1998) “The TCR-Binding Region of the HLA Class I α2 Domain Signals Rapid Fas-Independent Cell Death: A Direct Pathway for T Cell-Mediated Killing of Target cells?” J. Immunol., 160:4343-4352. [cited by applicant]
Pittet et al. (2003) “Alpha3 Domain Mutants of Peptide/MHC Class I Multimers Allow the Selective Isolation of High Avidity Tumor-Reactive CD8 T cells,” J. Immunol., 171 :1844-1849. [cited by applicant]
Potter et al. (1989) “Substitution at residue 227 of H-2 class I molecules abrogates recognition by CD8-dependent, but not CD8-independent, cytotoxic T lymphocytes,” Nature, 337:73-75. [cited by applicant]
Poueymirou et al. (2007) “F0 generation mice fully derived from gene-targeted embryonic stem cells allowing immediate phenotypic analyses,” Nature Biotech., 25:91-99. [cited by applicant]
Quinn et al. (1997) “Virus-Specific, CD8+ Major Histocompatibility Complex Class 1—Restricted Cytotoxic T Lymphocytes in Lymphocytic Choriomeningitis Virus-Infected B2- Microglobulin-Deficient Mice,” J. Virol., 71 :8392… [cited by applicant]
Rack et al. (1997) “A Chromosome 14q11/TCRα/δ Specific Yeast Artificial Chromosome Improves the Detection Rate and Characterization of Chromosome Abnormalities in T- Lymphoproliferative Disorders,” Blood, 90(3):1233-124… [cited by applicant]
Raffegerst et al. (2009) “Diverse Hematological Malignancies Including Hodgkin-Like Lymphomas Develop in Chimeric MHC Class II Transgenic Mice,” PLoS ONE, 4:e8539, 12 pages. [cited by applicant]
Ravetech and Lanier (2000) “Immune Inhibitory Receptors,” Science, 290:84-89. [cited by applicant]
Reipert et al. (2009) “Opportunities and limitations of mouse models humanized for HLA class II antigens,” Thrombosis and Haemostasis, 7(Suppl. 1):92-97. [cited by applicant]
Ren et al. (2006) “Construction of bioactive chimeric MHC class I tetramer by expression and purification of human-murine chimeric MHC heavy chain and B2M as a fusion protein in [cited by applicant]
Restifo et al. (2012) “Adoptive immunotherapy for cancer: harnessing the T cell response,” Nature Reviews, 12:269-281. [cited by applicant]
Richman et al. (2009) “Structural features of T cell receptor variable regions that enhance domain stability and enable expression as single-chain ValphaVbeta fragments,” Mol. Immunol., 43:902-916. [cited by applicant]
Rock et al. (2016) “Present Yourself! By MHC Class I and MHC Class II Molecules,” Trends Immunol., 37(11):724-737. [cited by applicant]
Rodriguez-Cruz et al. (2011) “Natural Splice Variant of MHC Class I Cytoplasmic Tail Enhances Dendritic Cell-Induced CD8+ T-Cell Responses and Boosts Anti-Tumor Immunity,” PLoS ONE, 6:e22939, 10 pages. [cited by applicant]
Rohrlich et al. (2003) “HLA-B*0702 transgenic, H-2K [cited by applicant]
Rosano et al. (2005) “The three-dimensional structure of B2 microglobulin: Results from X-ray crystallography,” Biochim. Biophys. Acta, 1753:85-91. [cited by applicant]
Rosenberg et al. (2011) “Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer,” Clin. Cancer Res., 17:4550-4557. [cited by applicant]
Rothe et al. (1993) Functional expression of a human TCRβ gene in transgenic mice, Intl. Immunol., 5(1):11-17. [cited by applicant]
Rowen et al., (1996) “The Complete 685-Kilobase DNA Sequence of the Human β T Cell Receptor Locus,” Science, 272:1755-1762. [cited by applicant]
Rubio et al. (2004) “Cross-linking of MHC class I molecules on human NK cells inhibits NK cell function, segregates MHC I from the NK cell synapse, and induces intracellular phosphotyrosines,” J. Leukoc. Biol., 76:116-1… [cited by applicant]
Sallusto et al. (1999) “Two subsets of memory T lymphocytes with distinct homing potentials and effector functions,” Nature, 401:708-712. [cited by applicant]
Salter et al. (1989) “Polymorphism in the alpha3 domain of HLA-A molecules affects binding to CD8,” Nature, 338:345-347. [cited by applicant]
Salter et al. (1990) “A binding site for the T-cell co-receptor CD8 on the alpha 3 domain of HLA-A2,” Nature, 345:41-46. [cited by applicant]
Samberg et al. (1989) “The α3 domain of major histocompatibility complex class I molecules plays a critical role in cytotoxic T lymphocyte stimulation,” Eur. J. Immunol., 19(12):2349-2354. [cited by applicant]
Sanders et al. (1991) “Mutations in CD8 that Affect Interactions with HLA Class I and Monoclonal Anti-CD8 Antibodies,” J. Exp. Med., 174:371-379. [cited by applicant]
Santagata et al. (2000) “The genetic and biochemical basis of Omenn syndrome,” Immunological Reviews, 178:64-74. [cited by applicant]
Satyanarayana et al. (1988) “Genomic organization of the human T-cell antigen-receptor alpha/delta locus,” PNAS, 85:8166-8170. [cited by applicant]
Scardino et al. (2003) “In vivo study of the GC90/IRIV vaccine for immune response and autoimmunity into a novel humanised transgenic mouse,” British Journal of Cancer, 89:199-205. [cited by applicant]
Scheer et al. (2013) “Generation and utility of genetically humanized mouse models.” Drug Discovery Today, 18(23/24):1200-1211. [cited by applicant]
Schwarz et al. (1996) “RAG mutations in human B cell-negative SCID,” Science, 274(5284):97-99. [cited by applicant]
Sebzda et al. (1999) “Selection of the T Cell Repertoire,” Annu. Rev. Immunol., 17:829-874. [cited by applicant]
Shani et al. (2009) “Incomplete T-cell receptor-β peptides target the mitochondrion and induce apoptosis,” Blood, 113:3530-3541. [cited by applicant]
Shankar Pradhan and MAJUMDAR, (2016) “An Efficient Method for Generation of Transgenic Rats Avoiding Embryo Manipulation,” Molecular Therapy—Nucleic Acids, 5, e293:1-11 doi:10.1038/mtna.2016.9. [cited by applicant]
Shankarkumar (2004) “The Human Leukocyte Antigen (HLA) System,” Int. J. Hum. Genet., 4:91-103. [cited by applicant]
Sherman et al. (1992) “Selecting T Cell Receptors with High Affinity for Self-MHC by Decreasing the Contribution of CD8,” Science, 258:815-818. [cited by applicant]
Shields et al. (1998) “Functional comparison of bovine, murine, and human β [cited by applicant]
Shin et al. (2006) “Surface expression of MHC class II in dendritic cells is controlled by regulated ubiquitination,” Nature, 444:115-118. [cited by applicant]
Shinkai et al. (1992) “RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement,” Cell 68(5):855-67. [cited by applicant]
Shinohara et al. (2007) “Active integration: new strategies for transgenesis,” Transgenic Res., 16:333-339. [cited by applicant]
Shiroishi et al. (2003) “Human inhibitory receptors Ig-like transcript 2 (ILT2) and ILT4 compete with CD8 for MHC class I binding and bind preferentially to HLA-G,” PNAS, 100:8856-8861. [cited by applicant]
Shirwan et al. (1995) “Structure and Repertoire Usage of Rat TCR β-Chain Genes in T Cells Infiltrating Heart Allografts [cited by applicant]